刘延鹏, 李玲, 纪全江. 非小细胞肺癌患者血浆凝血酶激活的纤溶抑制物和组织因子途径抑制物及凝血酶原片段1+2的水平变化及临床意义 [J]. 中华检验医学杂志, 2012(5):466.doi: 10.3760/cma.j.issn.1009-9158.2012.05.017.
|
王明山, 杨丽红, 潘景业. 晚期肺癌患者化疗过程中抗凝血酶和纤溶功能的变化及意义 [J]. 中国肺癌杂志, 2007(3):226.
|
辛英才, 陈洪昌. 肺癌患者凝血四项和肿瘤标志物的变化与临床治疗和预后的关系 [J]. 中国实用医药, 2012(2):1.doi: 10.3969/j.issn.1673-7555.2012.02.001.
|
Komurcuoglu B, Ulusoy S, Gayaf M. Prognostic value of plasma D-dimer levels in lung carcinoma [J]. Tumori, 2011(6):743.
|
Zhao J, Zhao M, Jin B. Tumor response and survival in patients with advanced non-small-cell lung cancer:the predictive value of chemotherapy-induced changes in fibrinogen [J]. BMC Cancer, 2012(1):330.
|
张咏梅, 刘艳, 毛毅敏. 肺癌患者凝血系统功能的相关性研究 [J]. 河南科技大学学报(医学版), 2011(2):97.doi: 10.3969/j.issn.1672-688X.2011.02.006.
|
Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients [J]. Hamostaseologie, 2012(2):127.
|
Pangilinan J M. Venous thromboembolism in patients with cancer:an overview for pharmacists using a case-based approach [J]. Journal of Pharmacy Practice, 2010(4):294.
|
Battinelli E M, Murphy D L, Connors J M. Venous thromboembolism overview [J]. Hematol Oneol Clin North Am, 2012(2):345.
|
Kuderer N M, Ortel T L, Francis C W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival [J]. Journal of Clinical Oncology, 2009, (29):4902.
|
李笑, 万里燕, 申洪. 血清甲状腺转录因子-1蛋白的变化特点及在肺癌诊断中的意义分析 [J]. 南方医科大学学报, 2011, (31):1952.
|
左一俊, 蔡雷鸣, 关乃福. COX-2在非小细胞肺癌中的表达及意义 [J]. 实用临床医药杂志, 2012, (16):11.doi: 10.3969/j.issn.1672-2353.2012.11.041.
|
江联萍. 多西他赛单药一线治疗晚期非小细胞肺癌疗效观察 [J]. 实用临床医药杂志, 2012, (16):63.doi: 10.3969/j.issn.1672-2353.2012.05.021.
|